Morgan Stanley
TVTX icon

Morgan Stanley’s Travere Therapeutics TVTX Stock Holding History

Morgan Stanley’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.96M Sell
301,655
-1,114,242
-79% -$33.3M ﹤0.01% 3656
2025
Q4 		$54.1M Buy
1,415,897
+298,860
+27% +$9.72M ﹤0.01% 2007
2025
Q3 		$26.7M Sell
1,117,037
-451,507
-29% -$8.49M ﹤0.01% 2605
2025
Q2 		$23.2M Sell
1,568,544
-73,517
-4% -$1.22M ﹤0.01% 2655
2025
Q1 		$29.4M Sell
1,642,061
-8,542
-0.5% -$173K ﹤0.01% 2302
2024
Q4 		$28.8M Buy
1,650,603
+301,195
+22% +$5.33M ﹤0.01% 2388
2024
Q3 		$18.9M Sell
1,349,408
-2,140,254
-61% -$22.3M ﹤0.01% 2854
2024
Q2 		$28.7M Sell
3,489,662
-37,958
-1% -$256K ﹤0.01% 2283
2024
Q1 		$27.2M Sell
3,527,620
-4,744,960
-57% -$40M ﹤0.01% 2356
2023
Q4 		$74.4M Buy
8,272,580
+6,032,243
+269% +$43.9M ﹤0.01% 2028
2023
Q3 		$20M Buy
2,240,337
+1,441,558
+180% +$20.3M ﹤0.01% 2443
2023
Q2 		$12.3M Sell
798,779
-95,091
-11% -$1.73M ﹤0.01% 2970
2023
Q1 		$20.1M Buy
893,870
+201,666
+29% +$4.29M ﹤0.01% 2413
2022
Q4 		$14.6M Buy
692,204
+319,136
+86% +$6.76M ﹤0.01% 2664
2022
Q3 		$9.19M Sell
373,068
-212,705
-36% -$5.5M ﹤0.01% 3072
2022
Q2 		$14.2M Buy
585,773
+99,831
+21% +$2.51M ﹤0.01% 2672
2022
Q1 		$12.5M Buy
485,942
+174,135
+56% +$4.62M ﹤0.01% 2648
2021
Q4 		$9.68M Sell
311,807
-69,128
-18% -$1.95M ﹤0.01% 2977
2021
Q3 		$9.24M Buy
380,935
+243,852
+178% +$4.48M ﹤0.01% 2989
2021
Q2 		$2M Buy
137,083
+110,710
+420% +$2.18M ﹤0.01% 4631
2021
Q1 		$657K Sell
26,373
-33,697
-56% -$931K ﹤0.01% 4996
2020
Q4 		$1.64M Buy
60,070
+35,032
+140% +$818K ﹤0.01% 4317
2020
Q3 		$462K Sell
25,038
-9,750
-28% -$190K ﹤0.01% 4689
2020
Q2 		$710K Buy
34,788
+3,682
+12% +$58.6K ﹤0.01% 4405
2020
Q1 		$453K Sell
31,106
-52,500
-63% -$790K ﹤0.01% 4434
2019
Q4 		$1.19M Buy
83,606
+42,130
+102% +$538K ﹤0.01% 4418
2019
Q3 		$480K Buy
41,476
+20,491
+98% +$339K ﹤0.01% 4699
2019
Q2 		$422K Sell
20,985
-11,413
-35% -$225K ﹤0.01% 4694
2019
Q1 		$733K Sell
32,398
-170,297
-84% -$3.76M ﹤0.01% 4321
2018
Q4 		$4.59M Buy
202,695
+127,658
+170% +$3.18M ﹤0.01% 3006
2018
Q3 		$2.16M Sell
75,037
-92,378
-55% -$2.64M ﹤0.01% 3943
2018
Q2 		$4.56M Buy
167,415
+4,717
+3% +$126K ﹤0.01% 3244
2018
Q1 		$3.64M Buy
162,698
+70,467
+76% +$1.68M ﹤0.01% 3390
2017
Q4 		$1.94M Sell
92,231
-32,912
-26% -$752K ﹤0.01% 4060
2017
Q3 		$3.12M Buy
125,143
+29,669
+31% +$653K ﹤0.01% 3446
2017
Q2 		$1.85M Buy
95,474
+38,145
+67% +$692K ﹤0.01% 3876
2017
Q1 		$1.06M Sell
57,329
-89,881
-61% -$1.76M ﹤0.01% 4344
2016
Q4 		$2.79M Sell
147,210
-255,006
-63% -$5.22M ﹤0.01% 3612
2016
Q3 		$9M Buy
402,216
+356,545
+781% +$6.79M ﹤0.01% 2107
2016
Q2 		$813K Buy
45,671
+6,148
+16% +$99.5K ﹤0.01% 4127
2016
Q1 		$539K Buy
39,523
+15,051
+62% +$228K ﹤0.01% 4390
2015
Q4 		$472K Sell
24,472
-246,063
-91% -$4.92M ﹤0.01% 4587
2015
Q3 		$5.48M Buy
270,535
+48,411
+22% +$1.43M ﹤0.01% 2575
2015
Q2 		$7.36M Buy
222,124
+204,267
+1,144% +$5.59M ﹤0.01% 2420
2015
Q1 		$428K Sell
17,857
-5,638
-24% -$86K ﹤0.01% 4767
2014
Q4 		$287K Buy
23,495
+22,299
+1,864% +$231K ﹤0.01% 5027
2014
Q3 		$11K Sell
1,196
-13,613
-92% -$160K ﹤0.01% 6169
2014
Q2 		$174K Buy
14,809
+14,719
+16,354% +$199K ﹤0.01% 5232
2014
Q1 		$2K Buy
+90
New +$1.38K ﹤0.01% 6351

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley's TVTX Position: Q1 2026 in Review

Morgan Stanley reduced its Travere Therapeutics (TVTX) stake by 79% in Q1 2026, selling an estimated $33.3M and leaving 301,655 shares worth $8.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

Morgan Stanley first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $74.4M in Q4 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Morgan Stanley held 301,655 shares of Travere Therapeutics worth $8.96M as of Q1 2026.
  • Morgan Stanley sold 1,114,242 Travere Therapeutics shares in Q1 2026, an estimated $33.3M.
  • Travere Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3656 holding.
  • Morgan Stanley first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Morgan Stanley's Travere Therapeutics position peaked at $74.4M in Q4 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.